“As far as we know, we’re the first commercial-stage company that has oncology biomarker offerings in both circulating tumor cells and circulating tumor DNA,” claims Biocept CEO Michael Nall.
The company is involved in the increasingly active “liquid biopsy” space, which uses blood samples instead of invasive tissue...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?